Clinical implications of acellular mucin pools in resected rectal cancer with pathological complete response to neoadjuvant chemoradiation

Colorectal Disease

Volumn 14, Issue 1, 2012, Pages 62-67

  de Campos Lobato, L F ^a   Dietz, D W ^a   Stocchi, L ^a   Vogel, J D ^a   Lavery, I C ^a   Goldblum, J R ^a   Skacel, M ^b   Pelley, R J ^b   Kalady, M F ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Dahl Chase Pathology Associates   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Mucin; Neoadjuvant treatment; Prognosis; Radiotherapy; Rectal cancer; Surgery; Tumour response

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; MUCIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECTUM CANCER; RECTUM CARCINOMA; RECTUM RESECTION; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCINS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECTAL NEOPLASMS;

EID: 83255192268     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2010.02532.x     Document Type: Article

References (24)

1. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-40.
2. Minsky BD, Cohen AM, Enker WE et al. Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Int J Radiat Oncol Biol Phys 1997; 37: 289-95.
3. Minsky BD, Cohen AM, Kemeny N et al. Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J Clin Oncol 1992; 10: 1218-24.
4. de Campos-Lobato LF, Stocchi L, da Luz Moreira A et al. Downstaging without complete pathologic response after neoadjuvant treatment improves cancer outcomes for cIII but not cII rectal cancers. Ann Surg Oncol 2010; 17: 1758-66.
5. Garcia-Aguilar J, Hernandez de Anda E, Sirivongs P et al. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 2003; 46: 298-304.
6. Capirci C, Valentini V, Cionini L et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008; 72: 99-107.
7. Das P, Skibber JM, Rodriguez-Bigas MA et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 2007; 109: 1750-5.
8. Edge SB, Byrd DR, Compton CC et al. (2010) AJCC - Cancer Staging Manual. Springer, New York.
9. Stipa F, Chessin DB, Shia J et al. A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol 2006; 13: 1047-53.
10. Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-23.
11. Kalady MF, de Campos-Lobato LF, Stocchi L et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 2009; 250: 582-9.
12. de Campos-Lobato LF, Geisler D, da Luz Moreira A et al. Neoadjuvant therapy for rectal cancer: the impact of longer interval between chemoradiation and surgery. J Gastrointest Surg 2011; 15: 444-50.
13. Farhat MH, Barada KA, Tawil AN et al. Effect of mucin production on survival in colorectal cancer: a case-control study. World J Gastroenterol 2008; 14: 6981-5.
14. Glasgow SC, Yu J, Carvalho LP et al. Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. Br J Cancer 2005; 92: 259-64.
15. Negri FV, Wotherspoon A, Cunningham D et al. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol 2005; 16: 1305-10.
16. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1: 1479-82.
17. Lavery IC, Lopez-Kostner F, Pelley RJ et al. Treatment of colon and rectal cancer. Surg Clin North Am 2000; 80: 535-69, ix.
18. Lopez-Kostner F, Lavery IC, Hool GR et al. Total mesorectal excision is not necessary for cancers of the upper rectum. Surgery 1998; 124: 612-7. discussion 617-8.
19. Wu JS, Fazio VW. Management of rectal cancer. J Gastrointest Surg 2004; 8: 139-49.
20. Gunderson LL, Jessup JM, Sargent DJ et al. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010; 28: 264-71.
21. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 2002; 359: 1686-9.
22. Compton CC, Fielding LP, Burgart LJ et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 979-94.
23. Smith KD, Tan D, Das P et al. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg 2010; 251: 261-4.
24. Ahmad NR, Nagle D. Long-term results of preoperative radiation therapy alone for stage T3 and T4 rectal cancer. Br J Surg 1997; 84: 1445-8.